Clinical trial · Interventional
Implementation Strategies for Monitoring Adherence in Real Time
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Medication Adherence | — | UNRESOLVED | — |
| Symptoms and Signs | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conversational Agent/Chatbot | Device | — | UNRESOLVED |
| Usual Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention Arm
- description
- Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
- interventionNames
- Device: Conversational Agent/Chatbot
- type
- ACTIVE_COMPARATOR
- label
- Control Arm
- description
- Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
- interventionNames
- Other: Usual Care
Primary outcomes (1)
- measure
- Adherence
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patient (age \> 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib. * Patient possession of a mobile device that can send/receive SMS texts * Ability to respond to questions and engage with "Penny" in English * Ability to provide informed consent to participate in the study * Approval from the patient's medical oncologist to be approached Exclusion Criteria: * Inability to respond to questions and engage with "Penny" in English * Inability or unwillingness to provide informed consent to participate in the study * Inability to engage with SMS text-messaging platform * Concurrent enrollment in a therapeutic clinical trial * Taking more than one oral targeted therapy or concurrent chemotherapy during the study window * Lack of approval from the patient's oncologist
References
Publications (0)
Data not yet available